Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) has been assigned a consensus rating of “Buy” from the six research firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, three have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $14.67.
AUPH has been the topic of a number of research analyst reports. BidaskClub lowered Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 25th. Zacks Investment Research raised Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.75 price objective on the stock in a research note on Wednesday, January 9th. Finally, ValuEngine raised Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 16th.
NASDAQ:AUPH traded down $0.30 during mid-day trading on Friday, reaching $6.31. The company’s stock had a trading volume of 20,390 shares, compared to its average volume of 1,176,325. Aurinia Pharmaceuticals has a twelve month low of $5.01 and a twelve month high of $7.85. The firm has a market cap of $565.16 million, a price-to-earnings ratio of -6.88 and a beta of 1.38.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. FMR LLC lifted its stake in shares of Aurinia Pharmaceuticals by 2.1% in the 3rd quarter. FMR LLC now owns 4,680,959 shares of the biotechnology company’s stock valued at $31,082,000 after purchasing an additional 95,650 shares in the last quarter. Polar Capital LLP lifted its stake in shares of Aurinia Pharmaceuticals by 17.8% in the 4th quarter. Polar Capital LLP now owns 3,312,723 shares of the biotechnology company’s stock valued at $22,593,000 after purchasing an additional 501,207 shares in the last quarter. Franklin Resources Inc. lifted its stake in shares of Aurinia Pharmaceuticals by 6.1% in the 3rd quarter. Franklin Resources Inc. now owns 1,838,500 shares of the biotechnology company’s stock valued at $12,208,000 after purchasing an additional 105,300 shares in the last quarter. D. E. Shaw & Co. Inc. raised its holdings in shares of Aurinia Pharmaceuticals by 47.3% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 388,811 shares of the biotechnology company’s stock valued at $2,652,000 after buying an additional 124,940 shares during the period. Finally, Creative Planning raised its holdings in shares of Aurinia Pharmaceuticals by 10.2% during the 4th quarter. Creative Planning now owns 167,657 shares of the biotechnology company’s stock valued at $1,143,000 after buying an additional 15,457 shares during the period. 25.08% of the stock is currently owned by institutional investors and hedge funds.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.
Featured Article: Why is cost of goods sold important?
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.